We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 27 for:    Saved Studies
Previous Study | Return to List | Next Study

Safety, Tolerance and Immunogenicity of EuCorVac-19 for the Prevention of COVID-19 in Healthy Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04783311
Recruitment Status : Active, not recruiting
First Posted : March 5, 2021
Last Update Posted : February 14, 2023
Sponsor:
Information provided by (Responsible Party):
EuBiologics Co.,Ltd

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Phase I/II study to determine safety, tolerance and immunogenicity of EuCorVac-19, a recombinant protein vaccine, for the prevention of COVID-19 in healthy adults

Condition or disease Intervention/treatment Phase
Covid19 Biological: EuCorVac-19 Other: Normal Saline Phase 1 Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 280 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Phase 1/2 Dose-exploration, Randomized, Observer-blind, Placebo-controlled Study to Determine Safety, Tolerance and Immunogenicity of EuCorVac-19, a Recombinant Protein Vaccine, for the Prevention of COVID-19 in Healthy Adults
Actual Study Start Date : February 23, 2021
Actual Primary Completion Date : October 15, 2021
Estimated Study Completion Date : June 30, 2023

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Phase 1 - EuCorVac-19 Low dose group
Healthy adults received two intramuscular doses (0.5mL per dose) with 3-week interval
 Biological: EuCorVac-19
Two intramuscular doses (0.5mL per dose) at 3-week interval

Other: Normal Saline
Two intramuscular doses (0.5mL per dose) at 3-week interval
Experimental: Phase 1 - EuCorVac-19 High dose group
Healthy adults received two intramuscular doses (0.5mL per dose) with 3-week interval
 Biological: EuCorVac-19
Two intramuscular doses (0.5mL per dose) at 3-week interval

Other: Normal Saline
Two intramuscular doses (0.5mL per dose) at 3-week interval
Experimental: Phase 2 - EuCorVac-19 Low dose group
Healthy adults received two intramuscular doses (0.5mL per dose) with 3-week interval
 Biological: EuCorVac-19
Two intramuscular doses (0.5mL per dose) at 3-week interval
Experimental: Phase 2 - EuCorVac-19 High dose group
Healthy adults received two intramuscular doses (0.5mL per dose) with 3-week interval
 Biological: EuCorVac-19
Two intramuscular doses (0.5mL per dose) at 3-week interval
Active Comparator: Phase 2 - Placebo comparator group
Healthy adults received two intramuscular doses (0.5mL per dose) with 3-week interval
 Other: Normal Saline
Two intramuscular doses (0.5mL per dose) at 3-week interval


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Immediate AEs [ Time Frame: within 30 minutes after each IP dosing ]
  2. Solicited local and systemic AEs [ Time Frame: for 7 days after each IP dosing ]
  3. Unsolicited AEs [ Time Frame: within 28 days after the last IP dosing ]
  4. SAEs [ Time Frame: within 52 weeks after the last IP dosing ]
  5. AESIs [ Time Frame: within 52 weeks after the last IP dosing ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Individuals who voluntarily decide to participate in this study and provide written informed consent

    • Healthy male and female adult at the age of 19 to 50 years (Part A)
    • Healthy male and female adult at the age of 19 to 75 years (Part B)
  2. Individuals who are available for all visit procedures including telephone visits during the study period

Exclusion Criteria:

  1. COVID-19 positive based on RT-PCR using upper respiratory tract or lower respiratory tract sampling or COVID-19 antibody positive
  2. History of SARS-CoV, MERS-CoV or SARS-CoV-2 infection
  3. History of vaccination against SARS-CoV, MERS-CoV or SARS-CoV-2
  4. Immune system disorders including immunodeficiency disease
  5. Clinically significant abnormalities in clinical laboratory test, ECGs and chest X-ray during screening in the opinion of the investigator
  6. Fever within 3 days prior to screening or serious acute or chronic infection within 7 days prior to screening requiring systemic antibiotics or antivirals
  7. Evidence or history of serious acute, chronic, or progressive disease which, in the opinion of the investigator, makes the individual ineligible for the study
  8. History of severe allergic reactions or severe hypersensitivity reactions to the IP or any of its components
  9. History of therapy that might affect immunity: treatment with immunosuppresants or immune modifying drugs, anticancer therapy, or radiotherapy within 3 months prior to screening
  10. Women of childbearing potential who do not agree to use medically allowed methods of contraception or to be heterosexually inactive until 60 days after the last dose of the IP
  11. Pregnant or breastfeeding woman
  12. Treatment with other IPs within 6 months prior to participation in this study
  13. Other reasons including medical reasons based on which the individual is considered to be ineligible for this study in the opinion of the investigator
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04783311


Locations
Layout table for location information
Korea, Republic of
The Catholic University of Eunpyeong St.Mary's Hospital
Seoul, Korea, Republic of
Sponsors and Collaborators
EuBiologics Co.,Ltd
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: EuBiologics Co.,Ltd
ClinicalTrials.gov Identifier: NCT04783311    
Other Study ID Numbers: EuSNAP_COV101
First Posted: March 5, 2021    Key Record Dates
Last Update Posted: February 14, 2023
Last Verified: December 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
 Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases